Potassium Ion

Potassium Ion

SCHEMBL640516

C[Si](C)(C)[NH-].C[Si](C)(C)[NH-].[K+].[K+]

nearest known ligand 0.30

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium Ion SCHEMBL8433562 1.00
Lithium Ion SCHEMBL395589 0.86
SCHEMBL31511971 0.86 ALDH1A1 (0.30) ALDH1A1
SCHEMBL1750165 0.86
SCHEMBL639786 0.86 ALDH1A1 (0.30) ALDH1A1
SCHEMBL1207561 0.86 ALDH1A1 (0.30) ALDH1A1
Lithium Ion SCHEMBL318795 0.86 ALDH1A1 (0.30) ALDH1A1
SCHEMBL9304336 0.86 ALDH1A1 (0.30) ALDH1A1
SCHEMBL9641891 0.86 ALDH1A1 (0.30) ALDH1A1
Zinc Ion SCHEMBL917737 0.86 ALDH1A1 (0.30) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121574120-A Oraglycone Process for the preparation of intermediates 杭州诺澳生物医药科技有限公司 2026-02-27 CN claimed
WO-2022156784-A1 PREPARATION METHOD FOR HETEROCYCLIC COMPOUND, AND INTERMEDIATE OF HETEROCYCLIC COMPOUND 武汉人福创新药物研发中心有限公司 2022-07-28 WO claimed
WO-2022156783-A1 PREPARATION METHOD FOR IMIDAZOPYRIDINE COMPOUND AND INTERMEDIATE THEREOF 武汉人福创新药物研发中心有限公司 2022-07-28 WO claimed
WO-2022095823-A1 FUNCTIONALIZED FLUOROALKYL SILANE, AND SYNTHETIC METHOD THEREFOR AND APPLICATION THEREOF 华东师范大学 2022-05-12 WO claimed
US-6034247-A REACTIG A UNSATURSATED CARBOXYLATED AMINE WITH A BASE; CYCLIZATION THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2000-03-07 US claimed
CN-116529417-B Novel compound, precursor composition comprising same, and method for producing thin film using same 韩松化学株式会社 2026-05-15 CN disclosed
CN-118459372-A Preparation method of photoacid generator sulfonate for ARF photoresist 常州朗芯新材料科技有限公司 2024-08-09 CN disclosed
CN-117700387-A Rockwell-like alcohol compound, intermediate, preparation method and application 深圳湾实验室 2024-03-15 CN disclosed
CN-113912577-B Rockwell intermediate, rockwell and its derivative, and preparation and application 深圳湾实验室 2023-12-29 CN disclosed
CN-116529417-A Novel compound, precursor composition comprising same, and method for producing thin film using same 韩松化学株式会社 2023-08-01 CN disclosed
WO-2022095823-A1 FUNCTIONALIZED FLUOROALKYL SILANE, AND SYNTHETIC METHOD THEREFOR AND APPLICATION THEREOF 华东师范大学 2022-05-12 WO disclosed
US-20200392135-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2020-12-17 US disclosed
EP-0662481-A1 Spiro piperidines and homologs promote release of growth hormone MERCK & CO. INC. (US) 1995-07-12 EP disclosed
US-5371215-A 4-substituted azetidinones as precursors to 2-substituted-3-carboxy carbapenem antibiotics and a method of producing them AMERICAN CYANAMID COMPANY (US) 1994-12-06 US disclosed
WO-1994019367-A1 SPIRO PIPERIDINES AND HOMOLOGS PROMOTE RELEASE OF GROWTH HORMONE MERCK & CO., INC. (US) 1994-09-01 WO disclosed
US-5189158-A 4-SUBSTITUTED AZETIDINONES AS PRECURSORS TO 2-SUBSTITUTED-3-CARBOXY CARBAPENEM ANTIBIOTICS AND A METHOD OF PRODUCING THEM AMERICAN CYANAMID COMPANY (US) 1993-02-23 US disclosed
EP-0504612-A2 Novel 4-substituted azetidinones as precursors to 2-substituted-3-carboxy carbapenem antibiotics and a method of producing them AMERICAN CYANAMID COMPANY (US) 1992-09-23 EP disclosed
US-5145855-A Hypotensive, memory deficit, asthma, psorisis HOECHST ROUSSEL PHARMACEUTICALS, INC. (US) 1992-09-08 US disclosed
US-5093336-A Treatment of cardiac failure and memory deficit HOECHAT-ROUSSEL PHARMACEUTICALS, INC. (US) 1992-03-03 US disclosed
EP-0406789-A1 6-and 7-Deoxyforskolin and derivates thereof, intermediates and a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1991-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392135-A1 ORGANIC COMPOUNDS HTR2C, HTR2A, HTR3A ALDH1A1 1117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.